Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Biofrontera Completes Patient Enrollment Of Phase 3 Study Of Ameluz Topical Gel, 10% For Actinic Keratoses On Extremities\

Author: Benzinga Newsdesk | March 18, 2025 09:31am

First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremities
Protocol involves one or two PDT treatments using 1-3 tubes of Ameluz® or vehicle gel over a surface area of up to 240 cm2
- Treatment phase expected to be complete by Q3 2025

Posted In: BFRI